Journals / Nöropsikiyatri Arşivi / 2019 / Cilt: 56 - Sayı: 1

Plasma Neuropeptide-S Levels in Populations Diagnosed with Generalized Anxiety Disorder: A Controlled Study

Yaygın Anksiyete Bozukluğu Tanılı Bireylerde Plazma Nöropeptid-S Düzeyleri: Bir Kontrollü Çalışma

Pages
52–56
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A receiver operating characteristic(ROC) analysis revealed that the plasma NPS levels could enable theidentification of GAD with 67.5% sensitivity and 62.5% specificity, whenthe cut-off value was determined as 25.06 pg/mL.Conclusions: Our results support the view that plasma NPS levels, whichhas demonstrated anxiolytic effects on the central nervous system, isrelated to the severity of anxiety in GAD and could be considered as acandidate marker for the identification of GAD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Neuropeptide S (NPS) is a novel neuropeptide reported tobe involved in fear-and stress-related conditions and their correspondingneuroendocrine processes.
📊
Key Findings & Data:The aim of this study was to compare theplasma NPS levels in patients suffering from generalized anxiety disorder(GAD) and those of healthy controls.Methods: A total of 40 subjects diagnosed with GAD and 40 healthycontrols were recruited in the study.
💡
Conclusion & Impact:A receiver operating characteristic(ROC) analysis revealed that the plasma NPS levels could enable theidentification of GAD with 67.5% sensitivity and 62.5% specificity, whenthe cut-off value was determined as 25.06 pg/mL.Conclusions: Our results support the view that plasma NPS levels, whichhas demonstrated anxiolytic effects on the central nervous system, isrelated to the severity of anxiety in GAD and could be considered as acandidate marker for the identification of GAD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Neuropeptide S (NPS) is a novel neuropeptide reported tobe involved in fear-and stress-related conditions and their correspondingneuroendocrine processes. The aim of this study was to compare theplasma NPS levels in patients suffering from generalized anxiety disorder(GAD) and those of healthy controls.Methods: A total of 40 subjects diagnosed with GAD and 40 healthycontrols were recruited in the study. The Hamilton Anxiety Scale (HAM-A),Generalized Anxiety Disorder-7 (GAD-7), and Hamilton DepressionScale (HAM-D) were administered to all participants to determine theseverity of participants’ anxiety and concomitant depressive symptoms.The plasma NPS levels were measured from the fasting venous bloodsamples obtained from each participant.Results: The median plasma NPS level was found to be significantlyhigher in the GAD group in comparison to the control group (28.8 pg/mL as against 19.1 pg/mL, p=0.01). A significant positive correlation wasobserved between the plasma NPS levels and HAM-A scores (rs=0.23,p=0.04) as well as the GAD-7 scores (rs=0.28, p=0.01). The p-valueobtained from the correlation analysis between the plasma NPS levelsand HAM-D scores was 0.052. A receiver operating characteristic(ROC) analysis revealed that the plasma NPS levels could enable theidentification of GAD with 67.5% sensitivity and 62.5% specificity, whenthe cut-off value was determined as 25.06 pg/mL.Conclusions: Our results support the view that plasma NPS levels, whichhas demonstrated anxiolytic effects on the central nervous system, isrelated to the severity of anxiety in GAD and could be considered as acandidate marker for the identification of GAD.

Özet

Amaç: Neuropeptide-S (NPS), korku, stres ilişkili durumlar ve bunlarla bağlantılı nöroendokrin süreçlerde yer aldığı gösterilmiş yeni bir nöropeptiddir. Bu çalışmada, yaygın anksiyete bozukluğu (YAB) olan bireylerde plazma nöropeptid-S (NPS) seviyelerinin, sağlıklı bireylerle karşılaştırılarak araştırılması amaçlanmıştır. Yöntem: Çalışmaya YAB tanısı konulmuş olan 40 hasta ile 40 sağlıklı kontrol vakası alınmıştır. Her iki gruba anksiyete ve eşlik eden depresyon düzeylerinin ölçümü amacıyla Hamilton Anksiyete Değerlendirme Ölçeği (HAM-A), Yaygın Anksiyete Bozukluğu-7 Testi (YAB-7), ve Hamilton Depresyon Değerlendirme Ölçeği (HAM-D) uygulanmıştır. Plazma NPS seviyeleri, her katılımcıdan aç karnına alınmış olan venöz kan örneklerinden ölçülmüştür. Bulgular: Hasta grubunda ortanca plazma NPS seviyeleri kontrol grubuna göre anlamlı düzeyde yüksek bulunmuştur (hasta grubunda 28,8 pg/ml iken kontrol grubunda 19,1 pg/ml, p=0,01). Plazma NPS seviyeleri ile HAM-A ve GAD-7 skorları arasında pozitif korelasyon tespit edilmiştir (HAM-A ile rs=0,23, p=0,04; GAD-7 ile rs=0,28, p=0,01). Plazma NPS seviyeleri ile HAM-D skorları arasındaki korelasyon analizi sonucu p=0,052 olarak saptanmıştır. ROC analizinde, plazma NPS seviyelerinin 25,06 pg/ml kesim değeri ile %67,5 duyarlılık ve %62,5 özgüllük oranında GAD tanısını belirleyebildiği değerlendirilmiştir. Sonuç: Çalışmamızın sonucu, santral sinir sisteminde anksiyolitik etkili olduğu gösterilmiş olan NPS’nin plazma düzeylerinin YAB’daki anksiyete şiddeti ile ilişkili olduğunu ve tanısal bir belirteç adayı olabileceğini destekler niteliktedir.

🔖

Cite This Article

KARA, H., KARLIDERE, T., DURMAZ, O., BAYKAN, H., BAYKAN, Ö., HIŞMIOĞULLARI, A. A. (2022). Plasma Neuropeptide-S Levels in Populations Diagnosed with Generalized Anxiety Disorder: A Controlled Study. Nöropsikiyatri Arşivi, Cilt: 56 - Sayı: 1, 52–56. https://ajindex.com/articles/579330

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Tyrer P, Baldwin D. Generalised anxiety disorder. The Lancet 2006;368:2156– 2166. [CrossRef] 2. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002;16:162–171. [CrossRef] 3. Newman MG, Llera SJ, Erickson TM, Przeworski A, Castonguay LG. Worry and generalized anxiety disorder: a review and theoretical synthesis of evidence on nature, etiology, mechanisms, and treatment. Annu Rev Clin Psychol 2013;9:275–297. https://doi.org/10.1146/annurev-clinpsy-050212-185544 4. Culpepper L. Generalized anxiety disorder and medical illness. J Clin Psychiatry 2009;70 Suppl 2:20–24. 5. Stein MB. Neurobiology of generalized anxiety disorder. J Clin Psychiatry 2009;70 Suppl 2:15–19. 6. Habib KE, Gold PW, Chrousos GP. Neuroendocrinology of stress. Endocrinol Metab Clin North Am 2001;30:695–728. 7. Xu YL, Reinscheid RK, Huitron-Resendiz S, Clark SD, Wang Z, Lin SH, Brucher FA, Zeng J, Ly NK, Henriksen SJ, de Lecea L, Civelli O. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 2004;43:487–497. [CrossRef] 8. Pape HC, Jüngling K, Seidenbecher T, Lesting J, Reinscheid RK. Neuropeptide S: a transmitter system in the brain regulating fear and anxiety. Neuropharmacology 2010;58:29–34. [CrossRef] 9. Duangdao DM, Clark SD, Okamura N, Reinscheid RK. Behavioral phenotyping of neuropeptide S receptor knockout mice. Behav Brain Res 2009;205:1–9. [CrossRef] 10. Smith KL, Patterson M, Dhillo WS, Patel SR, Semjonous NM, Gardiner JV, Ghatei MA, Bloom SR. Neuropeptide S stimulates the hypothalamo-pituitaryadrenal axis and inhibits food intake. Endocrinology 2006;147:3510–3518. [CrossRef] 11. Adori C, Barde S, Bogdanovic N, Uhlen M, Reinscheid RR, Kovacs GG, Hokfelt T. Neuropeptide S- and Neuropeptide S receptor-expressing neuron populations in the human pons. Front Neuroanat 2015;9:126. [CrossRef] 12. Yao Y, Su J, Zhang F, Lei Z. Effects of central and peripheral administration of neuropeptide s on the level of serum proinflammatory cytokines in pigs. Neuroimmunomodulation 2014;21:45–51. [CrossRef] 13. Donner J, Haapakoski R, Ezer S, Melen E, Pirkola S, Gratacos M, Zucchelli M, Anedda F, Johansson LE, Söderhall C, Orsmark-Pietras C, Suvisaari J, MartinSantos R, Torrens M, Silander K, Terwilliger JD, Wickman M, Pershagen G, Lönnqvist J, Peltonen L, Estivill X, D’Amato M, Kere J, Alenius H, Hovatta I. Assessment of the neuropeptide S system in anxiety disorders. Biol Psychiatry 2010;68:474–483. [CrossRef] 14